Rinvoq Biosimilar Race: Launch Timeline, Pricing Floor, and Who Files First Ahead of 2033

Rinvoq (upadacitinib) is AbbVie's second-act oral JAK1 inhibitor and its most important long-duration asset. Humira lost US exclusivity in January 2023 and has since shed nearly two-thirds of its peak revenue. Rinvoq was the explicit hedge — a newer-mechanism, broader-indication replacement designed to absorb the Humira patient base as biosimilars ate the market.

It worked better than AbbVie's own guidance predicted. Rinvoq grew 58% year-over-year in 2025 and is now approved for seven autoimmune indications, including rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, and giant cell arteritis. The expansion of the atopic dermatitis indication into pediatric patients in 2025 opened a materially larger prescription base than most analysts had modeled.

Which is exactly why the biosimilar race is starting now, not in 2031. The economic prize is too big for generic manufacturers to wait and be second.

The Patent Landscape: What Actually Expires in 2033

Rinvoq is protected in the US by a layered IP estate. The composition-of-matter patent on upadacitinib itself expires December 19, 2033. A method-of-use patent for the extended-release oral formulation runs through 2036. Several downstream formulation and crystalline-form patents extend into the late 2030s.

AbbVie has run this playbook before. With Humira, the company stacked more than 130 patents around the core molecule, creating a "patent thicket" that forced biosimilar entrants into settlement negotiations that pushed US biosimilar launches to 2023 — roughly seven years after the composition patent expired. Every biosimilar maker who tried to litigate ate legal fees for three to five years and still settled.

Rinvoq's thicket is thinner. It has roughly 30 Orange Book listings compared to Humira's layered estate. Analysts at Evaluate Vantage currently model a realistic first-biosimilar launch window between Q1 2034 and Q3 2035, assuming the composition patent is not extended and no late-stage formulation patents successfully block entry.

Who's Filing — And Who Files First Matters

Six companies have disclosed active Rinvoq biosimilar programs. The first-to-file advantage in biosimilars is real: the FDA grants 12 months of "interchangeable" exclusivity to the first biosimilar that demonstrates interchangeability with the reference product. That effectively gives the first filer a one-year window where they are the only substitutable generic — pharmacy benefit managers can default to their product at the counter without physician re-prescribing.

Celltrion is the clear frontrunner and has the most aggressive timeline. The company's Humira biosimilar (Yuflyma) launched in the US in July 2023 and captured roughly 14% of the Humira biosimilar market by end-2025 — above most analyst projections. Celltrion's manufacturing infrastructure for upadacitinib is already in partial buildout, a signal that management is committing real capital ahead of the revenue.

Sandoz is Celltrion's closest peer on timing. The Novartis spinout has been the more aggressive biosimilar filer since Hexal acquired it, and Sandoz's internal JAK1 expertise — built during its Rinvoq-adjacent research — gives it an unusual formulation shortcut.

Why AbbVie is quietly watching Amgen

Amgen's entry is the most interesting. Amgen is not a traditional biosimilar filer — most of its revenue comes from originator biologics. But the company has used biosimilars strategically: its Humira biosimilar Amjevita was the first to launch (January 2023) and captured significant early share. If Amgen commits to a Rinvoq biosimilar launch in 2034, it signals that the post-patent opportunity justifies the opportunity cost of an originator company putting R&D dollars into a knock-off.

The Pricing Floor and What It Does to AbbVie's Cash Flow

The Humira biosimilar wave compressed Humira's US net price by roughly 78% within the first 24 months of biosimilar availability, according to IQVIA analysis. A similar trajectory for Rinvoq — plausible given the number of filers and the aggressive PBM substitution landscape — implies that AbbVie's Rinvoq franchise could lose $4 billion to $5 billion of US revenue within 24 months of first biosimilar entry.

That revenue loss hits a company whose post-Humira operating income is already materially thinner. Rinvoq is currently responsible for roughly 11% of AbbVie's total revenue and — more critically — a disproportionate share of its gross margin because it has not yet absorbed the manufacturing overhead amortization Humira carries. Losing Rinvoq's contribution means AbbVie has to manufacture operating leverage from somewhere else.

AbbVie's visible response has been aggressive indication expansion, higher R&D spend on next-generation Skyrizi combinations, and the two 2025 oncology acquisitions (ImmunoGen and Cerevel). Whether that pipeline replaces Rinvoq's cash generation by 2035 is the real question shareholders should be modeling now, not in 2032.

What Pharmacy Decision-Makers Should Watch in 2026

Three near-term catalysts matter:

First: Celltrion's Phase 3 readout, expected H1 2027. If Celltrion's pharmacokinetic equivalence data is clean, it effectively locks in their first-to-file position. A messy readout — divergent exposure curves, formulation instability — opens the door to Sandoz or Amgen jumping ahead.

Second: any AbbVie secondary-patent litigation. AbbVie has signaled in analyst calls that it intends to enforce Rinvoq's extended-release formulation patents aggressively. A Paragraph IV certification filing from Celltrion or Sandoz in 2026 or 2027 will trigger the 30-month litigation stay — and the outcome of that litigation is the single biggest swing factor on actual US biosimilar launch timing.

Third: European biosimilar filings. Rinvoq's European composition patents expire earlier than US (late 2032). EMA filings in 2026-2027 will preview the actual clinical and manufacturing readiness of the biosimilar field. If European launches are smooth, US filers will move faster. If European filings surface clinical or immunogenicity issues, the US timeline slips.

AbbVie has until 2033 to replace Rinvoq. The biosimilar pipeline suggests they may have less time than that — 12 months of first-filer exclusivity aside, once the biosimilars start landing, the price compression happens fast. The playbook for managing this transition was written on Humira. The open question is whether AbbVie's next-generation pipeline fills the hole before the hole gets too big to fill.